S9922 Combination Chemo Plus Filgrastim With or Without Thalidomide in Refractory Multiple Myeloma
Status:
Terminated
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Thalidomide may stop the growth of tumor cells by stopping blood
flow to the tumor. It is not yet known if combination chemotherapy is more effective with or
without thalidomide for multiple myeloma.
PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy
with or without thalidomide in treating patients who have refractory multiple myeloma.